Stock MESO MESOBLAST LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Mesoblast Limited Nasdaq

Equities

MESO

US5907174016

Market Closed - Nasdaq
Other stock markets
 21:00:00 10/05/2024 BST 		5-day change 1st Jan Change
7.36 USD +2.65% Intraday chart for Mesoblast Limited -1.87% +234.55%
04-01 ADRs End Higher; Connect Biopharma Climbs 26% DJ
03-28 ADRs End Lower; NuCana Slides 15% DJ

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • Low profitability weakens the company.
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
MESOBLAST LIMITED Stock Mesoblast Limited
+234.55% 803M -
MODERNA, INC. Stock Moderna, Inc.
+17.96% 44.96B
B-
LONZA GROUP AG Stock Lonza Group AG
+48.77% 41.85B
A
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.17% 42.65B
B
CELLTRION, INC. Stock Celltrion, Inc.
-4.27% 29.04B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.42% 26.08B
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.39% 19.03B
B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+4.86% 12.75B
B+
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.29% 12.06B
C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.50% 11.75B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. MSB Stock
  4. MESO Stock
  5. Ratings Mesoblast Limited